DOCSLIB.ORG

Pathophysiology and Pharmacotherapy of Spasmodic Torticollis: a Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathophysiology and Pharmacotherapy of Spasmodic Torticollis: a Review LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Pathophysiology and Pharmacotherapy of Spasmodic Torticollis: A Review S. LAL SUMMARY: The few existing neuropa- ive evaluation of response, documentation INTRODUCTION thological, neurochemical, and neurophar- of key data, and adequacy of duration of "Spasmodic torticollis is an invo­ acological studies have shed little light follow-up make interpretation of published luntary hyperkinesis manifesting itself on the pathophysiology of spasmodic tor­ results difficult. Because of the heteroge­ ticollis (ST). The relevance of experimen­ neity of ST, investigations aimed at esta­ by mobile, tonic or clonic spasms of tal ST in animals and drug-induced ST in blishing a neurotransmitter profile for each the neck musculature, and producing a man to idiopathic ST is unclear. patient by observing the acute response to more or less stereotyped deviation of Most pharmacotherapeutic endeavors a test dose of drugs affecting cholinergic, the head into an abnormal position, have focused on drugs affecting basal gan­ dopaminergic, serotonergic, and gamma- the chin being rotated to one side or glia function. Unfortunately, problems of aminobutyric acid systems may provide a the head bent directly forward (ante- sample size, clinical heterogeneity of pa­ more rational basis to the selection of treat­ collis) or backward (retrocollis)" (Pat­ tient population, research design, object- ment. terson and Little, 1943). The etiology and site of a presumed central nervous system (CNS) lesion is unknown. Most pharmacotherapeutic endeavors have RfiSUMfi: Les rares etudes neuro- blies alleatoire: grandeur de I'echantillon- focused on drugs that affect basal gan­ pathologiques, neurochimiques et neuro- nage, heterogeneite clinique des popula­ glia function. Unlike Parkinson's dis­ pharmacologiques connues ne jettent que tions, plans de recherches, evaluation ob­ peu de lumiere sur la physiopathologie du jective des reponses, documentation de ease and Huntington's chorea where torticollis spasmodique (ST). La corres- donnees-clef, pertinence de la dure'e anatomical, chemical, and pharmaco­ pondance entre le ST experimental chez d'observation. A cause de I'heterogeneite logical information may provide a ra­ I'animal, le STinduitpardes medicaments, du ST, nous croyons qu'une batterie de tional basis for therapy, such an under­ et le ST idiopathique humain est encore tests qui aurait pour but d'evaluer, chez pinning of knowledge in spasmodic inconnue. chaque patient, la reponse aigu'i a des torticollis (ST) is lacking. Drug treat­ La plupart des essais pharmacothera- doses-essai de divers medicaments choli- ment is both advanced and discounted peutiques se sont concentres sur les medi­ nergiques, dopaminergiques, serotoniner- yet published results are few, contra­ caments agissant sur les fonctions des no- giqueset GABAergiques, offrirait unebase dictory, poorly controlled, and often yaux gris centraux. Plusieurs problemes plus valable pour la selection du traite- inadequately documented. rendent I'interpretation des resultats pu- ment approprie. The present paper discusses the pa­ thophysiology of ST and reviews in detail the available literature on the pharmacotherapy of this disorder. PATHOPHYSIOLOGY OF ST /. Neuroanatomical findings Psychological factors play a doubt­ ful role in the etiology of ST (Marsden, 1976; Mathews et al., 1978; Cockburn, 1971; Choppy-Jacolin et al., 1977). On the other hand, demonstration of a consistent pathological lesion remains elusive. Necropsy studies have been few. Lesions in the striatum, amongst other sites, have been described in From the Department of Psychiatry, Montreal Gen­ eral Hospital, Montreal three autopsied brains (Grinker and Walker, 1933; Foerster, 1933; Alpers Reprint requests to: Dr. S. Lai, Department of Psy­ chiatry, Montreal General Hospital, 1650 Cedar Street, and Drayer, 1937) as well as in two Montreal, Quebec H3G IA4, Canada. cases in which ST was part of a genera- Vol. 6 No. 4 NOVEMBER 1979 —427 Downloaded from https://www.cambridge.org/core. IP address: 170.106.35.76, on 25 Sep 2021 at 17:19:45, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0317167100023830 THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES lized dystonia (Cassirer, 1922; Wim- neuro-transmitter metabolism. Cur- nergic agents and drugs that enhance mer, 1929). However, the relevance of zon (1973) found a normal mean gamma-aminobutyric acid (GABA) these findings to the development of concentration of homovanillic acid function improved ST. ST is questioned (Tarlov, 1970). ST (HVA) and 5-hydroxyindoleacetic acid In the marmoset, in which the as­ has been associated with injury to the in lumbar cerebrospinal fluid (CSF) of cending DA fibers projecting from the cerebral cortex (David et al., 1952), 9 patients, whereas in a single case mesencephalic tegmentum to the colloid cyst of the third ventricle reported by Johansson and Roos ipsilateral striatum were lesioned with (Avman and Arasil, 1969), as well as (1974) there was a lowered value of 6-hydroxy-DA, amphetamine, an in­ with posterior fossa tumors (Winther, both acids. In ventricular CSF from 4 directly acting DA receptor agonist, 1930; Boisen, 1979). In the latter, patients with ST and 2 with dystonia worsened ST. Low doses of apomor­ clonic features were not described. musculorum deformans, HVA con­ phine, which may inhibit DA neuro­ These symptomatic cases may indicate centrations were intermediate between transmission (in contrast to large that lesions at several levels of the CNS non-neurological controls and Parkin­ doses, Tolosa, 1978), alleviated the may induce a clinical picture of ST. sonian patients (Papeschi et al., 1972). experimental condition. High doses of However, in the majority of cases of apomorphine reversed the direction of ST there is no demonstrable lesion. 4. Endocrinological findings in ST ST (Crossman and Sambrook, 1978). Hassler and Dieckman (1970) found ST may develop as a consequence of In the mid-brain lesioned cat the significant differences in cerebral hyperthyroidism and resolve with 5HT precursor, 5-hydroxytryptophan, hemispheric size on pneumoencepha­ treatment of the endocrine dysfunc­ worsened ST and L-dopa had no effect lography in 85% of cases. They specu­ tion (Gilbert, 1972a). Thyroxine in­ (Mori et al., 1975). lated that these radiological findings creases catecholamine receptor sensi­ indicated early brain damage which tivity, but whether such a mechanism 6. Drug-induced ST in man destroyed parts of the putamen (or accounts for the precipitation of ST in Neuroleptics (Ayd, 1961) as well as projections to the putamen) which a predisposed individual remains the benzamide derivative, metoclo- exert an inhibitory effect on contra- conjectural. In a single case of ST, pramide (Casteels-van Daele et al., versive head movements. This inhibi­ apomorphine, a DA receptor agonist, 1970) block DA receptors and induce a tory action may become ineffective failed to increase growth hormone variety of dystonic reactions including and ST become manifest. Unfor­ secretion (Brown et al., 1973). The ST in the early stages of treatment. tunately, the incidence of hemispheric significance of this isolated finding is Clinically, acute drug-induced ST is asymmetry in subjects without ST was unclear. predominantly tonic in nature. Swett not given. (1975) reported torticollis occurring in 5. Neuropharmacological studies in ex­ 35 out of 1152 patients receiving neu­ 2. Experimental ST perimental ST roleptics. In 20 cases of acute pheno- Focal brain stems lesions have been Neurotransmitter dysfunction has thiazine toxicity in childhood, four known to produce abnormal neck been investigated in experimental ST, had torticollis (Gupta and Lovejoy, postures in experimental animals but results do not lend themselves to 1967). These dystonic reactions res­ (Foltz et al., 1969; Carpenter, 1956; ready conclusions. Based on experi­ ponded rapidly to anticholinergic Denny-Brown, 1962; Poirier, 1960; ments in the monkey (Macaca mulat- agents (DiMascio et al., 1976), anti­ Mori et al., 1975; Battista et al., 1976; ta), in which ST was produced by elec­ histamines (Gupta and Lovejoy, Carrea and Mettler, 1955). Interrup­ trolytic lesions in the mesencephalic 1967; Cottom and Newman, 1966), tion of ascending dopamine (DA) tegmentum, Foltz et al. (1959) pos­ which are also potent anticholinergic fibers from the midbrain tegmentum tulated that a denervation hypersen­ agents, as well as to the indirectly in the marmoset induces severe torti­ sitivity of acetylcholine neurons which acting DA receptor agonists, aman­ collis with deviation of the head control postural movements of the tadine (DiMascio et al., 1976) and towards the side of the lesion, but head and neck was important in the methylphenidate (Fann, 1966). lesions in the pontine tegmentum, genesis of ST. However, anticholi­ ST may also develop as an isolated which affect ascending noradrenergic nergic agents failed to improve the complication of chronic neuroleptic neurons, induce contralateral torti­ experimental disorder. Anticholiner­ therapy (Chateau et al., 1966; Ha- collis (Crossman and Sambrook, gics, L-dopa, piribedil (indirectly renko, 1967) and can be considered as 1978). Tarlov (1970), examined brain acting DA receptor agonists), and a form of tardive dyskinesia. However, regions that have been implicated in apomorphine were ineffective in im­ whether chronic neuroleptic-induced the experimental
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep
    United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep. 10, 1985 54 BRAIN-SPECIFICDRUG DELIVERY 57 ABSTRACT 75 Inventor: Nicholas S. Bodor, Gainesville, Fla. The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug 73) Assignee: University of Florida, Gainesville, species to the brain, are: Fla. (a) compounds of the formula 21 Appl. No.: 516,382 22 Filed: Jul. 22, 1983 D-DHC) (I) Related U.S. Application Data wherein D is a centrally acting drug species, and 63 Continuation-in-part of Ser. No. 379,316, May 18, DHC is the reduced, biooxidizable, blood-brain 1982, Pat. No. 4,479,932, Ser. No. 461,543, Jan. 27, barrier penetrating lipoidal form of a dihydropyri 1983, , and Ser. No. 475,493, Mar. 15, 1983, , said Ser. dine - pyridinium salt redox carrier, with the No. 46,543, and Ser. No. 475,493, each is a continua proviso that when DHC) is tion-in-part of Ser. No. 379,316. 30 Foreign Application Priority Data O May 12, 1983 WO, PCT Int'l Appl. ......... WO83/00725 May 16, 1983 ICA) Canada ................................... 42892 51) Int. Cl...................... A61K 49/00; A61K 31/58; r’sN CO7J 17/00 52 U.S. Cl. ..................................... 424/9; 260/239.5; R 514/176 58 Field of Search .................. 424/9, 241; 260/239.5 wherein R is lower alkyl or benzyl and D is a drug species containing a single NH2 or OH func 56 References Cited tional group, the single OH group when present U.S.
    [Show full text]
  • Juvenile Huntington's Disease: a Case of Paternal Transmission With
    ISSN: 2378-3656 Agostinho et al. Clin Med Rev Case Rep 2019, 6:253 DOI: 10.23937/2378-3656/1410253 Volume 6 | Issue 1 Clinical Medical Reviews Open Access and Case Reports BRIEF REPORT Juvenile Huntington’s Disease: A Case of Paternal Transmission with an Uncommon CAG Expansion Luciana de Andrade Agostinho1,2,3*, Luiz Felipe Vasconcellos4, Victor Calil da Silveira4, Thays Apolinário1, Michele da Silva Gonçalves6,7, Mariana Spitz8 and Carmen Lúcia Antão Paiva1,5 1Programa de Pós-Graduação em de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil 2Centro Universitário Faminas, UNIFAMINAS, Muriaé, Brazil 3Hospital do Câncer de Muriaé - Fundação Cristiano Varella, Muriaé, Brazil 4Instituto de Neurologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 5Departamento de Genética e Biologia Molecular, Universidade Federal do Estado do Rio de Janeiro, Brazil Check for updates 6Laboratório Hermes Pardini, Belo Horizonte, Minas Gerais, Brazil 7Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil 8Serviço de Neurologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil *Corresponding author: Luciana de Andrade Agostinho, Programa de Pós-Graduação em de Neurologia, Universidade Federal do Estado do Rio de Janeiro; Centro Universitário Faminas, UNIFAMINAS; Hospital do Câncer de Muriaé - Fundação Cristiano Varella; Rua Manoel Francisco de Assis, 732, Muriaé (MG), CEP 36880000, Brazil, Tel: +55-32-998181209 Abstract Keywords Background: Juvenile HD (JHD) is the result of genetic CAG repeats, Juvenile Huntington’s disease, UHDRS, An- anticipation that occurs due to instability of CAG expanded ticipation alleles (HTT gene) when passed to the next generation, resulting in earlier onset of clinical manifestations in successive generations.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • The Dystonias
    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES SUBJECT REVIEW The Dystonias Edith G. McGeer and Patrick L. McGeer Can. J. Neurol. Sci. 1988; 15: 447-483 Contents This review is intended for both the practitioner and the sci­ entist. Its purpose is to summarize current knowledge regarding the various forms of dystonia, as well as the pathology known Introduction to produce the syndrome in specialized circumstances. Histopathological and brain imaging studies The low incidence of the disorder, its prolonged course, and the difficulty of accurate diagnosis has precluded the type of Sleep and other physiological studies systematic investigation that is possible with many other disor­ Chemical pathology ders. Yet such systematic investigation is essential if the myster­ Brain studies ies surrounding dystonia are to be unravelled and methods of CSF studies treatment improved. Blood studies Dystonia has been defined by the Scientific Advisory Board Urine studies of the Dystonia Medical Research Foundation as a syndrome of Fibroblast studies sustained muscle contraction, frequently causing twisting and Miscellaneous repetitive movements, or abnormal posture. It is a clinical term Therapy and not a disease description. It refers to all anatomical forms, whether they involve generalized musculature or only focal Iatrogenic dystonia groups. Although dystonia appears as part of the syndrome in a Possible animal models of dystonia number of disease states, it is idiopathic dystonia, where inheri­ Summary tance is a major factor, that has aroused the greatest medical interest. This review emphasizes recent literature and those aspects which may contribute to an understanding of the under­ 1. INTRODUCTION lying mechanisms of dystonic movement.
    [Show full text]
  • Recent Advances in the Treatment of Parkinson's Disease
    Recent advances in the treatment of Parkinsonism Parkinsons disease RICHARD J. MARTOCCI, D.O. Highland Park, Michigan ticholinergic drugs conventionally used to treat par- kinsonism, levodopa was three-and-a-half times as Although there are both medical and effective in relieving symptoms. However, the surgical methods of treating treatment of paralysis agitans, whether medical or parkinsonism, medical therapy should surgical, remains purely palliative and never is cura- be tried first and surgical measures tive. reserved for patients who do not respond. Anticholinergic drugs may be Pathophysiologic and biochemical aspects combined with an antihistamine when The pathologic alterations in parkinsonism the symptoms are mild, and levodopa (paralysis agitans) most consistently affect the zona used alone or with another drug when compacta2 of the substantia nigra with formation of the disease is moderate to severe. The Lewy bodies, or inclusion bodies, and neurofibril- side effects of levodopa are lary tangles3 such as those in Alzheimers disease and troublesome, and the clinical program other forms of senile atrophy. Histochemical studies must be adjusted constantly to achieve using fluorescent techniques have shown that maximum benefits and minimum side dopamine is almost nonexistent in the neostriatum effects. Pyridoxine reverses side effects and substantia nigra. Dopamine, a catecholamine, but also the benefits of levodopa. Use of has proved to be a neurohumeral transmitter. This a peripheral decarboxylase inhibitor suggests that in parkinsonism there is a decrease in may permit reduction in the dose of ability of affected brain tissue to form dopamine, levodopa to a point that side effects can and from 80 to 90 percent of dopamine in the brain be minimal.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Clinical Approach to Movement Disorders Wilson F
    REVIEWS The clinical approach to movement disorders Wilson F. Abdo, Bart P. C. van de Warrenburg, David J. Burn, Niall P. Quinn and Bastiaan R. Bloem Abstract | Movement disorders are commonly encountered in the clinic. In this Review, aimed at trainees and general neurologists, we provide a practical step-by-step approach to help clinicians in their ‘pattern recognition’ of movement disorders, as part of a process that ultimately leads to the diagnosis. The key to success is establishing the phenomenology of the clinical syndrome, which is determined from the specific combination of the dominant movement disorder, other abnormal movements in patients presenting with a mixed movement disorder, and a set of associated neurological and non-neurological abnormalities. Definition of the clinical syndrome in this manner should, in turn, result in a differential diagnosis. Sometimes, simple pattern recognition will suffice and lead directly to the diagnosis, but often ancillary investigations, guided by the dominant movement disorder, are required. We illustrate this diagnostic process for the most common types of movement disorder, namely, akinetic –rigid syndromes and the various types of hyperkinetic disorders (myoclonus, chorea, tics, dystonia and tremor). Abdo, W. F. et al. Nat. Rev. Neurol. 6, 29–37 (2010); doi:10.1038/nrneurol.2009.196 1 Continuing Medical Education online 85 years. The prevalence of essential tremor—the most common form of tremor—is 4% in people aged over This activity has been planned and implemented in accordance 40 years, increasing to 14% in people over 65 years of with the Essential Areas and policies of the Accreditation Council age.2,3 The prevalence of tics in school-age children and for Continuing Medical Education through the joint sponsorship of 4 MedscapeCME and Nature Publishing Group.
    [Show full text]
  • Symptomatic Dystonias Associated with Structural Brain Lesions: Report of 16 Cases
    Symptomatic Dystonias Associated with Structural Brain Lesions: Report of 16 Cases Vladimir S. Kostid, Marina Stojanovid-Svetel and Aleksandra Kacar ABSTRACT: Background: Symptomatic (secondary) dystonias associated isolated lesions in the brain provide insight into etiopathogenesis of the idiopathic form of dystonia and are a basis for establishing the possible correlation between the anatomy of a lesion and the type of dystonia according to muscles affected. Methods: In 358 patients with differently distributed dystonias, a group of 16 patients (4.5%) was encountered in whom dystonia was associated with focal brain lesions. Results: Of the 16 patients, 3 patients had generalized, 3 segmental and 4 hemidystonia, while the remaining 6 patients had focal dystonia. The most frequent etiologies were infarction in 7, and tumor in 4 patients. These lesions were usually found in the lenticular and caudate nucleus, thalamus, and in the case of blepharospasm in the upper brainstem. Conclusions: Our results support the suggestion that dystonia is caused by a dysfunc­ tion of the basal ganglia. RESUME: Dystonies symptomatiques associees a des lesions structurales du cerveau: a propos de 16 cas. Introduction: Les dystonies symptomatiques (secondaires) associees a des lesions cdrgbrales isoiees aident a com- prendre la pathogenese de la forme idiopathique de dystonie et servent de base a une correlation eventuelle entie la topographie de la lesion et le type de dystonie, selon sa distribution. M4thodes: Parmi 358 patients atteints de dys­ tonies a distribution varied, nous avons £tudie un groupe de 16 sujets (4.5%) chez qui la dystonie etait associee a des lesions focales du cerveau. Resultats: De ces 16 patients, 3 presentaient une dystonie g£n6ralisde, 3 prfisen- taient une dystonie segmentaire, 4 presentaient une hemidystonie et les 6 autres prtisentaient une dystonie focale.
    [Show full text]
  • Spasmodic Torticollis: a Case Report and Review of Therapies
    J Am Board Fam Pract: first published as 10.3122/jabfm.9.6.435 on 1 November 1996. Downloaded from MEDICAL PRACTICE Spasmodic Torticollis: A Case Report and Review of Therapies David 1. Smith, MD, and Maria C. DeMario, DO Background: Spasmodic torticollis is a movement disorder of the nuchal muscles, characterized by tremor or by tonic posturing of the head in a rotated, twisted, or abnormally flexed or exte.nded position or some combination of these positions. The abnormal posturing of the head allows this disorder to be clinically diagnosed. Psychiatric symptoms frequently accompany or precede the diagnosis of the movement disorder. Methods: Using the key words "torticollis," "spasmodic torticollis," "therapy," "behavior therapy," "botulinum toxin," MEDLINE was searched from 1989 to 1996 for information on the cause and treatment of spasmodic torticollis. Results and Conclusions: Therapies include behavior modification, such as biofeedback, hypnosis, or simply training the patient to consciously readjust the position of the head; pharmacotherapy, using a variety of agents, the most commonly prescribed being anticholinergic medications or the botulinum toxin type A; and surgery, which entails selectively denervating the muscles responsible for the abnormal move­ ment or posture of the head. The most effective treatments include surgery and botulinum, with sustained success rates ranging from approximately 60 to 90 percent. (J Am Board Fam Pract 1996;9:435-41.) Spasmodic torticollis is a clinically diagnosed Case Report movement disorder in which many authors de­ A 37-year-old woman, well-known to our office scribe psychologic accompaniments. The inci­ for her history of anxiety and phobias, came to dence is approximately 1 in 100,000, with either the office complaining that her head "wanted to an insidious or an abrupt onset.
    [Show full text]
  • Dystonia in Parkinson's Disease
    LIVING WITH Dystonia in Parkinson's Disease PARKINSON'S DISEASE Dystonia is a continuous or repetitive muscle twisting, spasm or cramp that can happen at different times of day. Curled, clenched toes or a painful, cramped foot are telltale signs of dystonia. Dystonia can occur in different stages of Parkinson’s disease (PD). For example, dystonia is a common early symptom of Young Onset Parkinson’s, but it can also appear in middle to advanced stages of Parkinson’s. What is Dystonia? Although dystonia can be a Parkinson’s symptoms, people can experience dystonia without having Dystonia often happens when the person with PD Parkinson’s. Whether or not a person with tries to perform an action with the affected body dystonia has Parkinson’s, it is often treated with part. For example, if you have dystonia of the the same medications. foot, you may feel fine when sitting, but you may Parts of the Body Affected by develop toe curling or foot inversion (turning in of the foot or ankle) when trying to walk or stand. Dystonia Dystonia can also happen when you are not using • Arms, hands, legs and feet: Involuntary the involved body part. Some dystonia happens movements, spasms or twisting and ""curling unrelated to an action or movement — like toe • Neck: May twist uncomfortably, causing the head curling while sitting. to be pulled down or to the side. This is called cervical dystonia or spasmodic torticollis People with PD often experience a painful dystonia on the side of their body with more • Muscles around the eyes: May squeeze Parkinson’s symptoms.
    [Show full text]
  • Surgical Strategies for Cervical Deformities Associated With
    Neurospine 2020;17(3):513-524. Neurospine https://doi.org/10.14245/ns.2040464.232 pISSN 2586-6583 eISSN 2586-6591 Review Article Surgical Strategies for Cervical Corresponding Author Deformities Associated With Yo on Ha https://orcid.org/0000-0002-3775-2324 Neuromuscular Disorders Department of Neurosurgery, Spine and 1 1 2 2 2 Spinal Cord Institute, Severance Hospital, Jong Joo Lee , Sung Han Oh , Yeong Ha Jeong , Sang Man Park , Hyeong Seok Jeon , 2 2 2 2 2 Yonsei University College of Medicine, 50 Hyung-Cheol Kim , Seong Bae An , Dong Ah Shin , Seong Yi , Keung Nyun Kim , 2 2 2 Yonsei-ro, Seodaemun-gu, Seoul 03722, Do Heum Yoon , Jun Jae Shin , Yoon Ha Korea 1Department of Neurosurgery, Bundang Jesaeng Hospital, Seongnam, Korea E-mail: [email protected] 2 Department of Neurosurgery, Spine and Spinal Cord Institute, Yonsei University College of Medicine, Seoul, Korea Co-corresponding Author Jun Jae Shin https://orcid.org/0000-0002-1503-6343 Neuromuscular disorders (NMDs) are diseases involving the upper and lower motor neu- Department of Neurosurgery, Spine and rons and muscles. In patients with NMDs, cervical spinal deformities are a very common Spinal Cord Institute, Severance Hospital, issue; however, unlike thoracolumbar spinal deformities, few studies have investigated Yonsei University College of Medicine, 50 these disorders. The patients with NMDs have irregular spinal curvature caused by poor Yonsei-ro, Seodaemun-gu, Seoul 03722, balance and poor coordination of their head, neck, and trunk. Particularly, cervical defor- Korea mity occurs at younger age, and is known to show more rigid and severe curvature at high E-mail: [email protected], junjaeshin@ cervical levels.
    [Show full text]